Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
June 05, 2024 08:00 ET
|
Assembly Biosciences, Inc.
-- Poster highlights promising preclinical profile of ABI-6250 ahead of entry into the clinic, expected by end of 2024 -- SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Assembly...
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
October 02, 2023 08:00 ET
|
Assembly Biosciences, Inc.
− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies...